Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by robertshawon Dec 13, 2019 12:56pm

116 Views

Post# 30452525

RE:RE:RE:RE:RE:RE:RE:RE:Forget news speculation; Mackie's report catapulted price!

Bunge wrote:
LaserStock29 wrote:

Longholder99 wrote: The Mackie report suggests to me that .80 is the bare minimum we can expect to see without any speculative SP advancement from good Ph2 results whixh we dont have yet, and other events they are not mathematically able to calculate value upon based on the current state of the company. Once the FDA approval and or Ph2 results start coming in these events will then be non speculative and part of the Mackie equation bringing their estimate up dramatically based on proposed NMIBC market share etc. Am I off here?

How many times ...

2014 sales pitch.. buy TLT at .30 get in this great opportunity. Private research IPO at $3 bucks..
Low float, no debt
Finishing Pre-Rats
Top Doctors
yada yada

2019 sales pitch buy TLT at .30 we're treating humans now
Have a fully funded ORF 4.5 m fund paying for the completion of preclin on 5 indications
US FDA very close
In 3 centres and have found 3 more in the onboarding process.

Ya... i think .80 is severly undervalued.

$3 isn't even bullish...... once you adjust for the opportunity cost and dilution......

these phase 2 results at 90 days just goes to fulfill the 2014 sales pitch and confirm what Theralase would of IPO'd at with a Nasdaq Listing

A listing years in the promising.

Sigh... 5 years of derisking... and you guys jizz to very very minor green days

At 60 cents before AGM we should have done 20M shares @ 50 cents with 1/2 warrant @ 70 for 2 years.

Little less cash (still $10M though) but we'd probably be 60 cents now with far less dilution and skepticism of management.

Would have been an easier path to CDN $3 (with the right results/news upcoming) for Nasdaq too.

So true. The idiot management just ruined this brilliant technology by its stupid decisions and screwed all the long shareholders. But in science we trust.

Bullboard Posts

High Tide adds two stores to undervalued cannabis retail network